– VIRAGE2 enrollment expected to complete in Q4 2026; initial data expected by Q3 2027 – – Company completes sale of SYN-004 (ribaxamase) and related portfolio of antibiotic-degrading enzymes to Biossil Labs Inc. in October, 2026 for $350,000 upfront and up to $91 million in aggregate milestones as well as royalties – – Detailed analyses of data from the VIRAGE Phase 2b clinical trial published in Nature Medicine – – Cash and cash equivalents of $8.5 million as of September 30, 2026; cash runway into Q1 202 ...